Navigation Links
Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics
Date:7/22/2009

GAITHERSBURG, Md., July 22 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has received an SBIR (small business innovation research) grant from National Cancer Institute (NCI), National Institute of Health (NIH), for its novel siRNA therapeutics to treat lung cancer. Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to advancing RNA interference (RNAi) Technology for novel targeted therapeutic development. The company's multi-targeted siRNA therapeutic programs utilizing its nanoparticle-enhanced delivery technologies represent a unique approach for truly realizing the advantages of small interfering RNA (siRNA)-based drugs to treat various critical human diseases. Sirnaomics has successfully attracted grants from NIH and the State of Maryland.

RNAi has emerged as a fundamentally important biological phenomenon and as a versatile, powerful tool for biomedical research. RNAi plays a multifaceted role in molecular biology by silencing genes through chromatin remodeling, interfering with protein synthesis, and in its best-studied mode of action quashing gene expression by cleaving messenger RNA. Experimental applications of RNAi have spurred the exploration of gene function in basic research, drug discovery and clinical settings. The 2006 Nobel Prize for medicine and physiology and a number of corporate acquisitions and investments by Novartis, Merck, AstraZeneca, Roche and Takeda have injected billions of dollars into this novel technology and further fueled the enthusiasm for the great promise of siRNA therapeutic development. There are more than a dozen clinical trials currently ongoing for various types of therapeutic applications.

Sirnaomics' mission is to advance RNAi technology by using its proprietary multi-targeted siRNA cocktail design together with the company's nanoparticle-mediated siRNA delivery vehicles in the rapid delivery of novel therapeutics. The company's proprietary "Tri-Blocker" technology for multi-targeted siRNA cocktail design and "Snano" series of nanoparticle delivery systems enable its advanced RNAi therapeutic programs for treatment of various diseases including H1N1/H5N1 influenza A infection, scarless wound healing and several types of cancers.

"Receiving an SBIR grant again from NCI clearly demonstrates the scientific and business merits of our lung cancer therapeutic program using multi-targeted siRNA cocktails," said Dr. Patrick Y. Lu, the founder, President and CEO of the company, also the Principal Investigator of the grant proposal. "It is a successful extension of Sirnaomics product pipeline for siRNA therapeutics." Dr. Lu further emphasized that the grants from various Government agencies provided a sustainable funding resource to the company in addition to its corporate partnership deals and venture capital investments. "Funding from Government is uniquely important for an early stage company like Sirnaomics, especially in the current financial environment."

Sirnaomics, Inc. is a privately held Delaware corporation headquartered in Gaithersburg, Maryland, USA. Established by a group of leading scientists in the field of RNAi technology, the company has a mission of advancing RNAi technology for novel drug discovery and targeted therapeutics development. Members of the senior management team bring over 50 years of combined experience in the biopharmaceutical, financial and business management industries in both the US and China and the company has established a subsidiary in Suzhou, China to expand both its R&D capacity and potential market.

    Contact:
    George J. Ji
    Sirnaomics, Inc.
    401 Professional Drive, Suite 130
    Gaithersburg, MD 20879, USA
    301-740-1730 Phone
    301-740-1731 FAX
    info-office@sirnaomics.com
   http://www.sirnaomics.com


'/>"/>
SOURCE Sirnaomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
2. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
3. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
4. TorreyPines Receives Notice of Delisting from Nasdaq Global Market
5. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
6. UCR physicist receives highest honor US government gives young scientists or engineers
7. Professor Fisher receives ASEEs Beer and Johnston Award
8. Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
9. Unisense FertiliTech A/S Receives CE Mark of Approval for EmbryoScope(TM) Embryo Monitoring System
10. WuXi PharmaTech Receives Award from BASF
11. AEterna Zentaris Receives US$10 Million from Institutional Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading ... a nationwide oncology Clinical Nurse Educator (CNE) network, which will ... need for communication among health care professionals to enhance the ... nurses, office staff, and other health care professionals to help ... breast cancer. ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... Dr. Bob ... at his local San Diego Rotary Club. The event entitled “Stem ... CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... of 13 prestigious awards honoring scientists who have made outstanding ... a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
Breaking Biology News(10 mins):